protein tyrosine phosphatase receptor type GGenealiases: HPTPG · PTPG · R-PTP-GAMMA · RPTPG
Q-omics provides the consensus-scored PTPRG profile across patient tissues and cancer cell-line models. PTPRG expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PTPRG is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, PTPRG RNA expression shows 19,644 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where PTPRG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPRG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPRG survival associations across molecular data types. PTPRG RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPRG RNA expression–survival associations across cancer types. High PTPRG expression shows unfavorable associations in MESO, BLCA, SARC and KICH, but favorable associations in KIRC and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PTPRG RNA expression.
This table summarizes PTPRG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTPRG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPRG shows lower tumor expression in LUAD, LUSC and BRCA and higher tumor expression in HNSC, LIHC and STAD. The HNSC box plot shows higher PTPRG RNA expression in tumor versus normal tissue (log2 FC = +1.491, t-test p < 0.001).
This table shows molecular features associated with PTPRG in patient tissues and cancer cell lines. In patient samples, PTPRG shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPRG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
